We previously reported that ST6GAL1 sialylates and activates EGFR in PDAC, ovarian, and colon cancer cell lines, as well as in nonmalignant cells (19–22), although an inhibitory effect of sialylation has also been reported (74, 75). Here, ST6GAL1 is linked to colonic neoplasm.